Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
KA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.22
N/A
-2.17
vs -6.79
Q4.22
+200%
7
vs -7.00
Q1.23
N/A
-0.77
vs -6.16
Q2.23
N/A
-0.08
vs -3.15
Q3.23
N/A
-0.46
vs -2.17
Q4.23
N/A
-0.19
vs 7
Q1.24
N/A
-0.89
vs -0.77
Q2.24
N/A
-0.20
vs -0.08
Q3.24
N/A
-0.23
vs -0.46
Q4.24
N/A
-0.24
vs -0.19
Sales Growth
YoY
Current
Estimates
Q3.22
-88%
200K vs 1.6M
Q4.22
-36%
487K vs 762K
Q1.23
-22%
281K vs 358K
Q2.23
+468%
5.2M vs 908K
Q3.23
-100%
NA vs 200K
Q4.23
-991%
-4338000.00 vs 487K
Q1.24
-100%
NA vs 281K
Q2.24
-100%
NA vs 5.2M
Q3.24
NA
300K vs NA
Q4.24
+107%
300K vs -4338000
Return on Equity
QoQ
Q3.22
+26%
0.26
vs 0.31
Q4.22
-1062%
-10.62
vs 0.26
Q1.23
+3896%
38.96
vs -10.62
Q2.23
+5%
0.05
vs 38.96
Q3.23
-198%
-1.98
vs 0.05
Q4.23
-92%
-0.92
vs -1.98
Q1.24
+160%
1.6
vs -0.92
Q2.24
+32%
0.32
vs 1.6
Institutionnal Ownership
accesswire.com
8 hours ago
prnewswire.com
17 hours ago
prnewswire.com
17 hours ago
Forecast
NaN%2025-Revenue
-575%2025-EPS
-185%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Quote Panel
Key Metrics
Relative Strength
KA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.
NASDAQ
Unprofitable
Unprofitable
-0.26Â ( -30.77%)
Pre-market 0.67$0.10 (16.56%)
Relative Strenght
9
Volume Buzz
-5%
Earning Acce
No
Dist 52w H.
89%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How KA compares to sector?
